A legal-news interview between Sarah Longwell and Ben Wittes centered on the Supreme Court’s temporary stay in the mifepristone case, Trump’s proposed $1.7 billion “weaponization” payout fund, DOJ efforts to shield Jeffrey Clark, and Kash Patel’s misconduct and credibility problems.
Watch on YouTube ›Get the market thesis, key claims, assets, contradictions, and follow-up questions from any financial video — then unlock a version personalized to your portfolio, watchlist, and favorite speakers.
Sarah Longwell and Ben Wittes framed the episode as a non-lawyer-friendly breakdown of major legal and political developments. The first long segment covered the Supreme Court’s temporary stay involving mifepristone (the abortion pill). Wittes explained the procedural posture: a Texas-originated challenge, the Fifth Circuit’s attempt to roll back FDA-related access via mail and telehealth, and the Supreme Court’s stay preserving the status quo while the Court decides whether to hear the case. …
Near term, the main actionable setup is the Supreme Court’s next move on mifepristone and the political backlash risk around Trump’s proposed compensation pool. Both are headline-sensitive and could intensify oversight, litigation, and fundraising narratives quickly.
Over the next few months, watch whether the mifepristone case becomes a major Supreme Court and campaign issue and whether the DOJ’s loyalty-driven posture expands. The base case in the transcript is continued institutional conflict, with Republican-aligned actors trying to protect allies and shape the public story.
Structurally, the episode argues that the regime is shifting toward personalized power: rewards for loyalists, erosion of independent accountability, and blurred lines between state power and patronage. That would matter long after any single legal case resolves.
The Supreme Court’s stay on the mifepristone ruling preserves the status quo for now rather than deciding the merits.
Wittes explains that the stay stops the Fifth Circuit ruling from taking effect while the Court considers whether to hear the case.
A Fifth Circuit merits loss could sharply reduce abortion-pill access nationwide, especially by limiting mail and telehealth distribution.
They argue the Fifth Circuit ruling would affect both abortion-ban states and access elsewhere.
Medication abortion now makes up a majority of abortions in the United States.
Wittes states this as part of explaining the significance of the access fight.
Can you give me an overview of the mifepristone case at the Supreme Court and what happened with the ruling?
Ben Wittes explains there has been a long-term effort by right-wing legal groups to get mifepristone banned. A Texas court rescinded the FDA's 20+ year approval, which was mostly overturned, but the Fifth Circuit let stand a ruling relaxing availability (allowing mail/telehealth distribution). The Supreme Court stayed that Fifth Circuit ruling temporarily while considering the case. The stay means the Fifth Circuit's decision does not go into effect, so mifepristone access via mail and telehealth continues for now.
Why is everyone freaking out about the ruling when it seems like it didn't change anything?
Wittes explains the Fifth Circuit opinion is a big deal because it would suspend access to mifepristone in all states where abortion is illegal and limit access everywhere else by banning mail and telehealth distribution. Mifepristone access has skyrocketed after Dobbs and is the main reason abortion numbers have gone up nationally. The Supreme Court's stay preserves the status quo of access for millions of people.
Is there anything to do now besides wait for the Supreme Court, or are there other actions that can be taken?
Wittes outlines three possibilities: (1) most likely — the Supreme Court grants cert and hears this as a blockbuster case next term; (2) unlikely — a summary disposition where the Court simply says the Fifth Circuit is wrong; (3) a third possibility of denying cert. He notes they usually don't do that with major federal policy questions.
Unlock the full claims, asset map, scores, related transcripts, follow-up questions, and AI chat — shaped around your portfolio, watchlist, favorite speakers, and risks.
